The Board of Pharmaron Beijing Co., Ltd. hereby announced that Mr. Dai Lixin ("Mr. Dai") and Ms. Chen Guoqin ("Ms. Chen") will cease to be the independent non-executive Director of the Company, with effect from the conclusion of the extraordinary general meeting of the Company to be held on September 23, 2022 (the "EGM"), in light of the upcoming expirations of their respective six-year consecutive terms of offices, as required according to the Rules for Independent Directors of Listed Companies of the China Securities Regulatory Commission. Immediately following Mr. Dai's and Ms. Chen's respective cessations of office, Mr. Dai will cease to be a member of the strategy committee of the Company, and Ms. Chen will also
cease to be the chairwoman of the nomination committee and the remuneration and appraisal committee of the Company, and a member of the audit committee of the Company.